[go: up one dir, main page]

AR122567A2 - LOW FREQUENCY THERAPY WITH GLATIRAMER ACETATE - Google Patents

LOW FREQUENCY THERAPY WITH GLATIRAMER ACETATE

Info

Publication number
AR122567A2
AR122567A2 ARP210101558A ARP210101558A AR122567A2 AR 122567 A2 AR122567 A2 AR 122567A2 AR P210101558 A ARP210101558 A AR P210101558A AR P210101558 A ARP210101558 A AR P210101558A AR 122567 A2 AR122567 A2 AR 122567A2
Authority
AR
Argentina
Prior art keywords
glatiramer acetate
multiple sclerosis
low frequency
patient
frequency therapy
Prior art date
Application number
ARP210101558A
Other languages
Spanish (es)
Inventor
Ety Klinger
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of AR122567A2 publication Critical patent/AR122567A2/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para aliviar un síntoma de esclerosis múltiple recurrente-remitente en un paciente humano que padece esclerosis múltiple recurrente-remitente o un paciente que ha experimentado un primer episodio clínico y para quien se ha determinado que corre un alto riesgo de desarrollar una esclerosis múltiple definida clínicamente, que comprende administrar al paciente humano tres inyecciones subcutáneas de una dosis terapéuticamente efectiva de acetato de glatiramer durante un período de siete días con un intervalo de por lo menos un día entre cada par de inyecciones subcutáneas para aliviar de esa manera los síntomas del paciente.A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and who has been determined to be at high risk of developing defined multiple sclerosis clinically, comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with an interval of at least one day between each pair of subcutaneous injections to thereby relieve the patient's symptoms .

ARP210101558A 2009-08-20 2021-06-08 LOW FREQUENCY THERAPY WITH GLATIRAMER ACETATE AR122567A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27468709P 2009-08-20 2009-08-20

Publications (1)

Publication Number Publication Date
AR122567A2 true AR122567A2 (en) 2022-09-21

Family

ID=82401567

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP210100616A AR121549A2 (en) 2009-08-20 2021-03-11 LOW FREQUENCY THERAPY WITH GLATIRAMER ACETATE
ARP210101558A AR122567A2 (en) 2009-08-20 2021-06-08 LOW FREQUENCY THERAPY WITH GLATIRAMER ACETATE

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP210100616A AR121549A2 (en) 2009-08-20 2021-03-11 LOW FREQUENCY THERAPY WITH GLATIRAMER ACETATE

Country Status (1)

Country Link
AR (2) AR121549A2 (en)

Also Published As

Publication number Publication date
AR121549A2 (en) 2022-06-15

Similar Documents

Publication Publication Date Title
AR077896A1 (en) LOW FREQUENCY THERAPY WITH GLATIRAMER ACETATE. USE. GLATIRAMER ACETATE.
NI201100147A (en) METHODS TO TREAT ACUTE MYOCARDIAL INFARCTIONS AND RELATED DISORDERS.
PE20142319A1 (en) MULTIPLE SCLEROSIS TREATMENT WITH A COMBINATION OF LAQUINIMOD AND GLATIRAMER ACETATE
PH12014500472A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX391565B (en) METHODS OF TREATMENT OF PATIENTS WITH FABRY DISEASE WHO HAVE RENAL FAILURE.
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
NI201100091A (en) PYRPHENIDONE TREATMENT FOR PATIENTS WITH ATYPICAL LIVER FUNCTION.
AR089862A1 (en) USE OF LAQUINIMOD FOR THE TREATMENT OF PATIENTS WITH CROHN'S DISEASE IN THOSE WHO FAILS AN ANTI-FACTOR THUMOR NECROSIS THERAPY a (ANTI-TNFa) FIRST LINE
PH12014500239A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MY166890A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CR9181A (en) ANTIANGIOGENESIS SELF-IMMUNITY THERAPY IN PATIENTS TO THOSE WHO PREVIOUS THERAPY FAILED
BR112013005673A2 (en) use of lysosomal acid lipase for treatment of lysosomal acid lipase deficiency in patients
CO6592015A2 (en) Methods and compositions to reduce or prevent vascular cladification during peritoneal dialysis treatment
RU2013123646A (en) COMBINED COMPOSITION
CO2017008395A2 (en) Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoate
ES2421709T3 (en) Use of bee venom to treat Parkinson's disease
BR112012000773A2 (en) METHOD FOR TREATMENT OF AT LEAST ONE CONDITION CHOSEN FROM PAIN, INFLAMMATION AND FEVER IN HUMAN PATIENTS METHOD FOR THE TREATMENT OF AT LEAST ONE CONDITION CHOSEN FROM PAIN, INFLAMMATION AND FEVER IN CRITICALLY ILL PATIENTS AT INCREASED RISK OF CARDIOVASCULAR EVENTS
AR122567A2 (en) LOW FREQUENCY THERAPY WITH GLATIRAMER ACETATE
EP4523750A3 (en) Methods of reducing cerebrovascular events in patients with fabry disease
EA201990217A2 (en) THERAPY WITH GLATIAMER ACETATE WITH LOW RATE
AR111971A1 (en) METHODS FOR TREATING PATIENTS WITH FABRY'S DISEASE WHO HAVE KIDNEY FAILURE
Koch Effective intermittent administration of nabiximols in a patient with autism (Asperger’s syndrome)
Kiselev Acute manic episode: case report
Unsel Bee venom allergy immunotherapy/carvedilol/perindopril
Iida Hypersensitivity: case report

Legal Events

Date Code Title Description
FC Refusal